Evidence map›Paper›PMID 35954426›Full record

ArticleCancers2022

External Quality Assessment 2.0: The Importance of a Standardized Implementation of TILs for Daily and Trial Practices.

Inne Nauwelaers, Nele Laudus, Dieter Peeters, Balazs Acs, Carsten Denkert, Stefan Michiels, Hugo Horlings, Kalliopi P Siziopikou, Scott Ely, Dimitrios Zardavas and 8 more

Abstract readEditorial
PubMed Full text at PMC Publisher
In one paragraph

Article in Cancers, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

18 authors.

Inne NauwelaersBiomedical Quality Assurance Research Unit, Department of Public Health and Primary Care, University of Leuven, Kapucijnenvoer 35d, 3000 Leuven, Belgium.ORCID 0000-0003-3577-6776
Nele LaudusBiomedical Quality Assurance Research Unit, Department of Public Health and Primary Care, University of Leuven, Kapucijnenvoer 35d, 3000 Leuven, Belgium.ORCID 0000-0001-6876-3475
Dieter PeetersCellCarta NV, 2610 Antwerp, Belgium.
Balazs AcsDepartment of Oncology and Pathology, Cancer Center Karolinska, Karolinska Institute, 171 64 Stockholm, Sweden.ORCID 0000-0002-0972-4633
Carsten DenkertInstitute of Pathology, Philipps-University Marburg and University Hospital Marburg (UKGM), Baldingerstr. 1, 35043 Marburg, Germany.
Stefan MichielsDepartment of Biostatistics and Epidemiology, Gustave Roussy, University Paris-Saclay, 94800 Villejuif, France.
Hugo HorlingsDivision of Molecular Pathology, The Netherlands Cancer Institute, 1066 CX Amsterdam, The Netherlands.
Kalliopi P SiziopikouDepartment of Pathology, Section of Breast Pathology, Northwestern University, Chicago, IL 60611, USA.
Scott ElyTranslational Medicine, Bristol-Myers Squibb, Princeton, NJ 08540, USA.
Dimitrios ZardavasOncology Clinical Development, Bristol-Myers Squibb, Princeton, NJ 08540, USA.
Roberts MustimboTranslational Medicine, Bristol-Myers Squibb, Princeton, NJ 08540, USA.
John BartlettEdinburgh Cancer Research Centre, Institute of Genetics and Molecular Medicine, Edinburgh EH4 2XR, UK.
Giuseppe FlorisLaboratory of Translational Cell & Tissue Research, Department of Imaging and Pathology, University of Leuven, 3000 Leuven, Belgium.
Johan HartmanDepartment of Oncology and Pathology, Cancer Center Karolinska, Karolinska Institute, 171 64 Stockholm, Sweden.ORCID 0000-0002-6500-8527
Carolien H M van DeurzenDepartment of Pathology, Erasmus Medical Center-Cancer Institute, 3015 GD Rotterdam, The Netherlands.
Dorien CeustersBiomedical Quality Assurance Research Unit, Department of Public Health and Primary Care, University of Leuven, Kapucijnenvoer 35d, 3000 Leuven, Belgium.ORCID 0000-0002-2436-0284
Els DequekerBiomedical Quality Assurance Research Unit, Department of Public Health and Primary Care, University of Leuven, Kapucijnenvoer 35d, 3000 Leuven, Belgium.ORCID 0000-0001-5383-3178
Roberto SalgadoDepartment of Pathology, GZA-ZNA Hospitals, 2610 Antwerp, Belgium.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Increasing data suggests that an intact immune system is required for improvedoutcomes in patients with Human Epidermal Growth Factor Receptor 2 (HER2+) and Triple Negative Breast Cancer (TNBC) [...].

Identifiers

PMID35954426
PMCPMC9367276

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.